Sodium–glucose cotransporter 2 (SGLT2) occurs in the proximal renal tubule cells. We investigate the hepatic expression of SGLT2 and its related factors in patients with chronic liver disease. This is a retrospective human study. The liver tissues were biopsied from patients with chronic liver disease (n = 30). The expression levels of SGLT2 were evaluated by immunostaining. Furthermore, the undirected graphical model was used to identify factors associated with hepatic expression levels of SGLT2. The SGLT2 expression was observed in not only the kidney, but also the liver in immunostaining (SGLT2 intensity: kidney 165.8 ± 15.6, liver 114.4 ± 49.0 arbitrary units, P < 0.01) and immunoblotting. There was no significant difference in hepatic expression of SGLT2 in the stratified analysis according to age, sex, BMI, and the severity of the liver disease. In the undirected graphical model, SGLT2 directly interacted with various factors such as sex, fatty change, neutrophil-to-lymphocyte ratio, triglyceride, hemoglobin A1c, creatinine, and albumin (partial correlation coefficient 0.4–0.6 for sex and 0.2–0.4 for others). The expression of SGLT2 was observed in the hepatocytes of patients with chronic liver disease. The undirected graphical model demonstrated the complex interaction of hepatic expression levels of SGLT2 with gender, inflammation, renal function, and lipid/glucose/protein metabolisms.

钠-葡萄糖协同转运蛋白 2 (SGLT2) 存在于近端肾小管细胞中。我们调查了慢性肝病患者中 SGLT2 的肝脏表达及其相关因素。这是一项回顾性人体研究。肝组织取自慢性肝病患者（n  = 30）。通过免疫染色评估 SGLT2 的表达水平。此外，无向图形模型用于识别与 SGLT2 肝脏表达水平相关的因素。SGLT2 表达不仅在肾脏，而且在免疫染色中也观察到肝脏（SGLT2 强度：肾脏 165.8 ± 15.6，肝脏 114.4 ± 49.0 任意单位，P < 0.01) 和免疫印迹。在根据年龄、性别、BMI和肝病严重程度进行的分层分析中，SGLT2的肝脏表达没有显着差异。在无向图形模型中，SGLT2 直接与各种因素相互作用，例如性别、脂肪变化、中性粒细胞与淋巴细胞的比率、甘油三酯、血红蛋白 A1c、肌酐和白蛋白（性别的偏相关系数为 0.4-0.6，其他的偏相关系数为 0.2-0.4 ）。在慢性肝病患者的肝细胞中观察到SGLT2的表达。无向图形模型展示了 SGLT2 肝脏表达水平与性别、炎症、肾功能和脂质/葡萄糖/蛋白质代谢的复杂相互作用。